3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Completed
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Endocrine
2
NET
1
Lymphoid
1
Conditions
Carcinoma, Transitional Cell
14
Urinary Bladder Neoplasms
13
Colorectal Neoplasms
10
Carcinoma, Merkel Cell
9
Breast Neoplasms
9
Carcinoma, Renal Cell
7
Neoplasms
6
Neoplasm Metastasis
6
Carcinoma, Non-Small-Cell Lung
6
Small Cell Lung Carcinoma
4
Carcinoma, Hepatocellular
4
Turcot syndrome
3
Stomach Neoplasms
3
Neuroendocrine Tumors
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Urethral Neoplasms
2
Ureteral Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Penile Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Melanoma
2
Lung Neoplasms
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Neuroendocrine
2
Uterine Cervical Neoplasms
1
Interventions
Everolimus
9
Cisplatin
8
Temozolomide
6
Nivolumab
5
Etoposide
5
Carboplatin
5
Bevacizumab
5
lutetium Lu 177 dotatate
4
Capecitabine
4
pembrolizumab
3
Irinotecan
3
sintilimab
2
dostarlimab
2
cabozantinib
2
azaspirane
2
avelumab
2
atezolizumab
2
Paclitaxel
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Ipilimumab
2
Immunoglobulin G
2
IFL protocol
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Disulfides
2
zimberelimab
1
surufatinib
1
selinexor
1
pertuzumab
1
pasireotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Neuroendocrine
×
avelumab
×
Clear all
NCT03352934
2022-02-25
AveNEC
Johannes Gutenberg University Mainz
Phase 2
Completed
60 enrolled
NCT03147404
2019-12-30
MS100070-0177
Samsung Medical Center
Phase 2
Completed
14 enrolled